Dexamethasone reduces oxygen induced retinopathy in a mouse model

Area of Science:

• Ophthalmology
• Neonatology
• Pharmacology

Background:

• Dexamethasone use in neonates is common but its effect on retinopathy of prematurity (ROP) remains controversial.
• Previous studies report conflicting outcomes regarding dexamethasone's impact on ROP, showing detrimental, protective, or no effect.

Purpose of the Study:

• To investigate if dexamethasone administered during the injury phase (oxygen exposure) mitigates the severity of oxygen-induced retinopathy (OIR).
• To test the hypothesis that early dexamethasone treatment reduces OIR severity in a mouse model.

Main Methods:

• C57BL6 mouse pups were exposed to hyperoxia (75% FiO2) or room air from postnatal day 7-12.
• Dexamethasone (0.5 mg/kg/d) was administered subcutaneously to some pups during oxygen exposure.
• Retinopathy was assessed using scoring systems and Periodic Acid-Schiff (PAS) staining on postnatal days 17-21.

Main Results:

• Dexamethasone-treated pups exposed to oxygen showed significantly lower retinopathy scores (median 5) compared to oxygen-exposed pups without treatment (median 9, p < 0.001).
• PAS staining revealed a significant reduction in extraretinal neovascularization in dexamethasone-treated pups (p = 0.04).
• Dexamethasone treatment led to decreased weight gain but did not adversely affect normal retinal vascular development.

Conclusions:

• Dexamethasone effectively decreases the severity of oxygen-induced retinopathy in a mouse model.
• The protective effect appears to occur during the hyperoxic injury phase, mitigating damage to developing retinal vasculature.
• Dexamethasone shows potential as a therapeutic agent for OIR, offering protection without compromising normal retinal vascular development.